Therapy development for ALS: lessons learned and path forward (Q37198692)

18 August 2017

1 reference

title

Therapy development for ALS: lessons learned and path forward (English)

1 reference

amyotrophic lateral sclerosis

18 August 2017

1 reference

1 reference

2

Merit Cudkowicz

1 reference

18 August 2017

Veena Lanka

1

1 reference

18 August 2017

1 June 2008

1 reference

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

3

1 reference

18 August 2017

131-140

1 reference

Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group

18 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Unraveling the mechanisms involved in motor neuron degeneration in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Mutant dynactin in motor neuron disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Design, power, and interpretation of studies in the standard murine model of ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Design of phase II ALS clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Clinical trials in ALS: what did we learn from recent trials in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Controlled trial of nimodipine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A clinical trial of verapamil in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

A pilot randomized trial of oxandrolone in inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Changes in expression of NMDA receptor subunits in the rat lumbar spinal cord following neonatal nerve injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Early signs of motoneuron vulnerability in a disease model system: Characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Detection method of the adjacent motor neuronal death in an in vitro co-culture model of familial ALS-associated Cu/Zn superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Animal models of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Transgenic animal models of neurodegenerative diseases and their application to treatment development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Identification of potential CSF biomarkers in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802112819

10.1080/17482960802112819

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18574756